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Introduction: 
The aim of the present study was to evaluate the efficacy and tolerability of vandetanib plus gemcitabine 
(V/G) compared with gemcitabine alone in elderly patients with untreated advanced non–small-cell lung 
cancer. 
Methods: 
This was a phase II, randomized, double-blind study. A total of 124 elderly patients (mean age, 75 yr; age 
range, 70–84 yr; 73% men) received V/G (n = 61) or placebo plus gemcitabine (n = 63). Progression-free 
survival (PFS) was the primary endpoint. Secondary endpoints were overall survival, objective response 
rate, duration of response, disease control rate, time to deterioration of performance status, and safety 
outcomes. 
Results: 
PFS was significantly prolonged with V/G (median, 183 days; 95% confidence interval, 116–214) compared 
with placebo plus gemcitabine (median, 169 days; 95% confidence interval, 95–194; p = 0.047). No 
statistically significant differences between arms were observed in all secondary endpoints, including 
overall survival. The addition of vandetanib to gemcitabine was well tolerated. The rate of patients with ≥1 
treatment-related adverse event was comparable in the two arms, pyrexia, dyspnea, and neutropenia 
being the most common adverse events. 
Conclusions: 
V/G combination was associated with a statistically significant prolongation of PFS compared with 
gemcitabine alone in untreated elderly patients with advanced non–small-cell lung cancer, with an 
acceptable safety profile. 
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Vandetanib is a novel small-molecule tyrosine kinase (TK) inhibitor with antiepidermal growth factor 
receptor, antivascular endothelial growth factor receptor-2, and anti-rearranged during transfection TK 
activity.1 In pretreated non–small-cell lung cancer (NSCLC) patients, vandetanib monotherapy did not show 
an overall survival (OS) advantage when compared with placebo2 and had a similar progression-free 
survival (PFS) when compared with erlotinib.3 Vandetanib showed a slight improvement in PFS when 
administered in association with docetaxel versus docetaxel alone4 and a trend to improved PFS with the 
combination vandetanib plus pemetrexed versus pemetrexed alone.5 However, both trials resulted in 
improved lung cancer symptom control. 
Although there is evidence that a platinum-based doublet may be effective,6 single-agent chemotherapy 
with a third-generation drug (e.g., vinorelbine, gemcitabine, or taxane) was, at the time of the start of 
study, a recommended option for unselected elderly patients with advanced NSCLC.7 A recently published 
meta-analysis on benefit-to-risk ratio of doublets in advanced NSCLC concluded that combination platinum-
based therapy in NSCLC patients more than 70 years old may be more favorable than single agents on 
overall response rate (ORR), but not on OS.8 
This phase II randomized, double-blind, placebo-controlled study was designed to determine whether the 
addition of vandetanib to gemcitabine, in comparison to gemcitabine as single agent, significantly prolongs 
PFS in untreated elderly patients with advanced NSCLC. 
METHODS 
This study included patients aged ≥70 years with confirmed stage IIIB/IV NSCLC (according to UICC TNM 
Classification of Malignant Tumours, 6th edition), anticancer therapy naïve, WHO PS (World Health 
Organization-performance status) of 0–2, measurable disease according to Response Evaluation Criteria in 
Solid Tumors, life expectancy ≥12 weeks, and no significant hematologic, hepatic, renal, or cardiac 
abnormalities. Patients with brain metastases were eligible if they had not received treatment within the 4 
weeks before entry and stable without steroid treatment for 10 days. Patients receiving any treatment 
known to have an effect on NSCLC (except palliative radiotherapy and bisphosphonates for bone 
metastases) within 4 weeks before the start of study were excluded. 
Written informed consent was obtained from each participant. The study was approved by the Ethics 
Committee of each site. 
Eligible patients were randomized 1:1 to receive vandetanib plus gemcitabine (V/G) or placebo plus 
gemcitabine (P/G). The computer-generated randomization scheme was strictly sequential with blocks of 
randomization codes being sent to each center according to the recruitment potential. 
Vandetanib or placebo was administered as single oral 100 mg daily doses. Gemcitabine was administered 
at a 1200 mg/m2 dose as an intravenous infusion on day 1 and day 8 of each 21-day cycle (maximum 6). 
Treatment was discontinued once a patient experienced disease progression or a ≥3 grade toxicity. 
Radiological evaluation using RECIST 1.0 was performed at baseline and every 6 weeks until progression. 
Primary endpoint of the study was PFS. Secondary endpoints were OS; ORR (complete response or partial 
response); duration of response; disease control rate (percentage of patients with complete response or 
partial response or stable disease ≥6 wk); and time to deterioration of performance status (TDPS, the time 
from randomization to a change from baseline ≥1). 
Safety analyses included adverse events (AEs), laboratory parameters, vital signs, and electrocardiogram. 
Assuming a median PFS of 3 months for gemcitabine,9 a minimum of 122 patients (61 per arm) were 
planned to detect a 50% prolongation with V/G (median PFS of 4.5 months), assuming an accrual period of 
12 months, a maximum follow-up time of 20 months, and no drop-outs. For this comparison, 110 
progression events were required. 
In the PFS analysis, survival curves, medians, and their 95% confidence intervals (CIs) were estimated 
applying the Kaplan-Meier method. The log-rank test was used to compare PFS outcomes. The Cox’s 
proportional hazard regression model was used to analyze covariates of interest (tumor stage, number of 
organs involved, prior adjuvant chemotherapy, histology, smoking history, gender, QTc prolongation, and 
tumor response). 
Time-dependent variables (OS, duration of response, and TDPS) were analyzed like PFS. The comparison 
between groups in ORR, disease control rate, and proportion of patients alive at 1-year postrandomization 
was performed by chi-square test. 
AEs were classified by primary system organ class according to the MedDRA thesaurus version 12. For 
continuous variables, the change from baseline to each postbaseline visit was calculated. 
RESULTS 
This study was conducted from October 2008 to December 2011 in 17 sites in Italy. Figure 1 shows the 
disposition of patients and reasons for withdrawal. Demographic and other baseline characteristics were 
comparable in the two arms (Table 1). 
  
 
 
 
 
 
 
 
 
 
FIGURE 1.  
Disposition of patients and reasons for withdrawal. *Patients may have more than one reason for 
withdrawal. AE, adverse event; DP, disease progression. 
TABLE 1.  
Summary of Demographic and Other Baseline Characteristics and of Tumor History 
 
Vandetanib/ Gemcitabine Placebo/ Gemcitabine 
 
n = 61 n = 63 
Sex, n (%) 
  
 Males 45 (73.8) 45 (71.4) 
 Females 16 (26.2) 18 (28.6) 
Age (yr), mean (range) 75.03 (70–82) 75.48 (70–84) 
WHO PS, n (%) 
  
 Vandetanib/ Gemcitabine Placebo/ Gemcitabine 
 
n = 61 n = 63 
 Grade 0 33 (54.1) 38 (60.3) 
 Grade 1 27 (44.3) 24 (38.1) 
 Grade 2 1 (1.6) 1 (1.6) 
Smoking history, n (%) 
  
 Never smoked 8 (13.1) 13 (20.6) 
 Current smokers 15 (24.6) 16 (25.4) 
 Past smokers 37 (60.7) 34 (54.0) 
 Missing 1 (1.6) — 
Previous radiotherapy, n (%) 13 (21.3) 8 (12.7) 
Type of tumor, n (%) 
  
 Squamous cell carcinoma 13 (21.3) 17 (27.0) 
 Adenocarcinoma 31 (50.8) 41 (65.1) 
 Bronchoalveolar carcinoma 3 (4.9) 1 (1.6) 
 Large cell carcinoma 2 (3.3) — 
 Other or missing 12 (19.6) 4 (6.3) 
Grade of histopathological diagnosis, n (%) 
  
 Well differentiated (grade 1) 4 (11.4) — 
 Moderately differentiated (grade 2) 4 (11.4) 4 (12.1) 
 Poorly differentiated (grade 3) 8 (22.9) 11 (33.3) 
 Unknown or missing 19 (54.3) 18 (54.6) 
 Vandetanib/ Gemcitabine Placebo/ Gemcitabine 
 
n = 61 n = 63 
Stage at study entry, n (%) 
  
 IIIB (supraclavicular lymph node metastases) 6 (9.8) 7 (11.1) 
 IV 55 (90.2) 56 (88.9) 
WHO PS, World Health Organization performance status. 
The median number of cycles of gemcitabine infusions was 4 (range, 1–6) in both arms, with a similar 
percentage of patients receiving the complete scheme of gemcitabine (40% for each arm). The median 
exposure was 78.5 days (range, 1–528) in the V/G arm and 91 days (range, 1–441) in the P/G arm. 
Table 2 summarizes efficacy results. Median PFS (Figure 2) was significantly prolonged in the V/G arm (183 
days; 95% CI, 116–214) compared with the P/G arm (169 days; 95% CI: 95–194; p = 0.047). In the V/G arm, 
10 patients (16.4%) were censored and 51 failed treatment, whereas five patients (7.9%) were censored 
and 58 failed in the P/G arm. The adjusted Cox regression analysis on PFS showed that only sex had a 
statistically significant effect (hazard ratio of female patients versus male patients: 0.63; 95% CI, 0.40–0.99; 
p = 0.043). The explorative analysis showed that median PFS was significantly prolonged in the V/G arm 
compared with the P/G arm for the following covariates: patients with all combined types of histological 
tumors except squamous cell carcinoma (V/G arm: 196 days; 95% CI, 160–245; P/G arm: 162 days; 95% CI, 
87–191; p = 0.008); never/past smokers (V/G arm: 188 days; 95% CI, 129–236; P/G arm: 169 days; 95% CI, 
99–194; p = 0.048); and female patients (V/G arm: 245 days; 95% CI, 175–693; P/G arm: 91.5 days; 95% CI, 
45–224; p = 0.010). 
TABLE 2.  
Summary of Results of Efficacy 
 
Vandetanlb/Gemcitabine Placebo/Gemcitabine 
 
n = 61 n = 63 pa 
PFS (days), median (95% CI) 183 (116–214) 169 (95–194) 0.047 
OS (days), median (95% CI) 262 (170–245) 305 (213–355) 0.896 
 Vandetanlb/Gemcitabine Placebo/Gemcitabine 
 
n = 61 n = 63 pa 
Alive at one year, n (%) 19 (31.1) 19 (30.2) 0.90 
Objective response, n (%) 9 (14.8) 8 (12.7) 0.74 
DOR (days), median (95% CI) 225 (175–0) 214 (124–232) 0.162 
Disease control, n (%) 44 (72.1) 42 (66.7) 0.51 
TDPS (days), median (95% CI) 167 (64–0) 111 (79–188) 0.659 
PFS, progression-free survival; CI, confidence interval; OS, overall survival; DOR, duration of 
response; TDPS, time to deterioration of performance status. 
a 
Log-tank test in survival function data and chi-square test in proportions. 
 
 
 
 
 
 
 
 
 
FIGURE 2.  
Progression-free survival: Kaplan-Meier estimate of survival distribution function—unadjusted. 
In the V/G arm, 37 patients (60.7%) had no World Health Organization-performance status increase from 
baseline and 24 (39.3%) had ≥1 point increase compared with 31 patients (49.2%) with no increase and 32 
(50.8%) with deterioration in the P/G arm. 
The rate of patients with at least one AE was 96.7% and 98.4% for arm V/G and P/G, respectively. Serious 
AEs were reported in 42.6% in arm V/G and 32.7% in arm P/G. 
Ten patients (16.4%) in arm V/G and eight (12.7%) in arm P/G died, mostly for disease progression. Dose 
adjustment, temporary interruption, or permanent discontinuation of study drug was required in 72.1% of 
V/G and 60.3% of P/G. Grade IV toxicities were reported in five patients (8.2%) in the V/G arm and in five 
(7.9%) in the P/G arm. Table 3 shows the most common AEs. Five patients (8.2%) in the V/G arm and two 
(3.2%) in the P/G arm had at least one QTc interval prolongation during the study. 
TABLE 3.  
Most Common AEs of Any Grade (i.e., Reported in ≥10% of Patients in Either Arm) and of Grade >3 
(i.e., Reported in >2% of Patients in Either Arm) 
 
Vandetanib/Gemcitabine Placebo/Gemcitabine 
n = 61 n = 63 
AEs of any grade 
  
 Pyrexia 17 (27.9) 17 (27.0) 
 Dyspnea 13 (21.3) 19 (30.2) 
 Neutropenia 17 (27.9) 14 (22.2) 
 Fatigue 14 (23.0) 15 (23.8) 
 Thrombocytopenia 14 (23.0) 13 (20.6) 
 Anorexia 8 (13.1) 17 (27.0) 
 Asthenia 9 (14.8) 13 (20.6) 
 Rash 15 (24.6) 5 (7.9) 
 Anemia 8 (13.1) 14 (22.2) 
 Vandetanib/Gemcitabine Placebo/Gemcitabine 
n = 61 n = 63 
 Diarrhea 9 (14.8) 9 (14.3) 
 Cough 9 (14.8) 10 (15.9) 
 Nausea 7 (11.5) 8 (12.7) 
 Edema peripheral 4 (6.6) 12 (19.0) 
 Chest pain 2 (3.3) 12 (23.8) 
 Vomiting 4 (6.6) 7 (11.1) 
 Hypokalemia 3 (4.9) 8 (12.7) 
Grade >3 AEsa 
  
 Neutropenia 7 (11.5) 8 (12.7) 
 Dyspnea 5 (8.2) 7 (11.1) 
 Fatigue 4 (6.6) 3 (4.8) 
 Anemia 3 (4.9) 2 (3.2) 
 Thrombocytopenia 4 (6.6) 2 (3.2) 
 Pulmonary embolism 3 (4.9) 3 (4.8) 
 Pneumonia 2 (3.3) — 
 Pulmonary edema 3 (4.9) — 
 Respiratory failure 1 (1.6) 2 (3.2) 
 Asthenia — 2 (3.2) 
 Rash 2 (3.3) — 
 Cerebral ischemia — 2 (3.2) 
Data are number (%) of patients 
AE, adverse event. 
a 
According to the NCI CTCAE, Version 3.0. 
DISCUSSION 
This study compared the efficacy and tolerability of treatment with vandetanib given in addition to 
gemcitabine versus gemcitabine plus placebo in 124 untreated elderly patients with advanced NSCLC and 
satisfactory health status and organ function. 
The two treatment groups were balanced in terms of demographic and baseline characteristics, including 
tumor staging and prognostic factors. Results of the primary endpoint showed that PFS was significantly 
prolonged in the V/G arm compared with P/G. The significant benefit in the V/G group was obtained 
despite the PFS in the control group was longer than expected.9 However, our assumption of a 50% PFS 
prolongation was not reached. 
The preplanned subgroups’ explorative analysis showed that PFS was significantly prolonged with V/G 
compared with P/G alone in patients with all types of histological tumors except squamous cell carcinoma, 
in never/past smokers and in female patients. However, it should be noted that the subpopulations, in 
which a statistically significant difference between arms was not observed, included a limited number of 
patients, which were likely not adequately powered for a reliable comparison between arms. Of all 
secondary endpoints, no statistically significant differences were found, including tumor response and 
survival. 
The addition of vandetanib to gemcitabine was associated with a satisfactory toxicity profile. Pyrexia, 
dyspnea, and neutropenia were the most common AEs and were observed in comparable rates in the two 
arms, being neutropenia and pyrexia the results of gemcitabine-induced myelosuppression and dyspnea a 
disease-related symptom. 
Among the other most common AEs related to vandetanib, the incidence of diarrhea was comparable in 
the two treatment arms, whereas skin rash was more frequent in patients in the V/G arm than in the P/G 
arm. In the present study, vandetanib may have caused rash in a lower proportion of patients than that 
previously reported.10 Among the cardiovascular side effects, less than 10% of patients treated with 
vandetanib reported increased blood pressure, with no cases of grade III–IV hypertension in either arm, 
and none of the patients with blood pressure elevation required treatment discontinuation, interruption, or 
delay due to this event. QT interval prolongation has also been reported in clinical trials with vandetanib,11 
particularly in view of the long terminal elimination half-life of the drug.12 In this study, a QTc interval 
prolongation was reported in five patients treated with vandetanib and in two in the control group. 
However, this event was not associated with an increase in risk of serious cardiac events in the V/G arm. 
To our knowledge, this is the first study conducted in elderly patients with vandetanib and the first 
evidence of its combination with gemcitabine. Consistent with previous trials,13 an improvement in PFS in 
the vandetanib arm did not translate into an improvement in OS. However, the group of patients who 
received vandetanib in this and in previous trials experienced a delay in TDPS, suggesting palliative benefits. 
Taking into account the results of this phase II study in terms of efficacy and safety, further research is of 
interest to better identify the group of patients who might benefit from vandetanib treatment. 
REFERENCES 
 
1. S Sathornsumetee, JN Rich 
Vandetanib, a novel multitargeted kinase inhibitor, in cancer therapy 
Drugs Today (Barc), 42 (2006), pp. 657–670 
2. JS Lee, V Hirsh, K Park, et al. 
Vandetanib versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an 
epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial 
(ZEPHYR) 
J Clin Oncol, 30 (2012), pp. 1114–1121 
3. RB Natale, S Thongprasert, FA Greco, et al. 
Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-
small-cell lung cancer 
J Clin Oncol, 29 (2011), pp. 1059–1066 
4. RS Herbst, Y Sun, WE Eberhardt, et al. 
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-
cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial 
Lancet Oncol, 11 (2010), pp. 619–626 
5. RH de Boer, Ó Arrieta, CH Yang, et al. 
Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a 
randomized, double-blind phase III trial 
J Clin Oncol, 29 (2011), pp. 1067–1074 
E Quoix 
Optimal pharmacotherapeutic strategies for elderly patients with advanced non-small cell lung cancer 
Drugs Aging, 28 (2011), pp. 885–894 
7. C Gridelli, M Aapro, A Ardizzoni, et al. 
Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel 
J Clin Oncol, 23 (2005), pp. 3125–3137 
8. G Des Guetz, B Uzzan, P Nicolas, D Valeyre, G Sebbane, JF Morere 
Comparison of the efficacy and safety of single-agent and doublet chemotherapy in advanced non-small 
cell lung cancer in the elderly: a meta-analysis 
Crit Rev Oncol Hematol, 84 (2012), pp. 340–349 
9. C Gridelli, F Perrone, C Gallo, MILES Investigators, et al. 
Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung 
Cancer in the Elderly Study (MILES) phase III randomized trial 
J Natl Cancer Inst, 95 (2003), pp. 362–372 
10. AC Rosen, S Wu, A Damse, E Sherman, ME Lacouture 
Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis 
J Clin Endocrinol Metab, 97 (2012), pp. 1125–1133 
11. JV Heymach, BE Johnson, D Prager, et al. 
Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non 
small-cell lung cancer 
J Clin Oncol, 25 (2007), pp. 4270–4277 
12. JE Frampton 
Vandetanib: in medullary thyroid cancer 
Drugs, 72 (2012), pp. 1423–1436 
13. WX Qi, LN Tang, AN He, Z Shen, Y Yao 
The role of vandetanib in the second-line treatment for advanced non-small-cell-lung cancer: a meta-
analysis of four randomized controlled trials 
Lung, 189 (2011), pp. 437–443 
 
 
 
